Increase in UK R&D spend led by pharma and biotech

12 March 2010

The top one thousand UK companies invested more than £26 billion ($39.26 billion) on developing new products, services and improving productivity in 2008, according to the latest R&D scoreboard published this month. The R&D Scoreboard is an annual investigation of the top 1,000 UK and top 1,000 global corporate investors in research and development.

Spend by the UK companies listed increased by 9.2% in 2008 compared with 2007. The increase was largely due to firms in the pharmaceuticals and biotechnology, aerospace and defence, software and computer services and banking sectors, the report found.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >